NICE green lights Tremfya to treat active psoriatic arthritis
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Read Moreby Lucy Parsons | May 28, 2021 | News | 0
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Read Moreby Selina McKee | Nov 26, 2020 | News | 0
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read Moreby Lucy Parsons | Oct 16, 2020 | News | 0
Treatment demonstrated positive outcomes for nearly five years
Read Moreby Selina McKee | Jul 15, 2020 | News | 0
The drug is the first IL-23 inhibitor approved for the condition
Read Moreby Anna Smith | Aug 15, 2019 | News | 0
The drug met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study.
Read Moreby Anna Smith | Aug 12, 2019 | News | 0
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
Read Moreby Anna Smith | Feb 28, 2019 | News | 0
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
Read Moreby Selina McKee | Dec 12, 2018 | News | 0
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis’ Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
Read Moreby Selina McKee | Jul 11, 2018 | News | 0
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
Read Moreby Selina McKee | Jun 14, 2018 | News | 0
The National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS.
Read Moreby Selina McKee | Jun 12, 2018 | News | 0
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read Moreby Selina McKee | May 11, 2018 | News | 0
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
